K. Burk
Impact in
-
- Nanoparticle-Based Drug Delivery
-
- Cancer Treatment and Pharmacology
Papers in
- Oncology 7
- Cancer Treatment and Pharmacology 6
-
- Electron Spin Resonance Studies 3
- Co-authors
- Klaus B. Mross (6 shared papers)D. K. Hossfeld (5 shared papers)Claus Bolling (1 shared paper)Feliksas Jankevičius (1 shared paper)Alvydas Česas (1 shared paper)Axel-Rainer Hanauske (1 shared paper)Marion Tina Weigel (1 shared paper)Wolf‐Hartmut Meyer‐Moldenhauer (1 shared paper)
- Journals
- Cancer Chemotherapy and Pharmacology (2 papers)Investigational New Drugs (2 papers)European Journal of Cancer (2 papers)Journal of Emergency Medicine (1 paper)European Journal of Clinical Pharmacology (1 paper)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
K. Burk
19 papers receiving 179 citations
Peers
Comparison fields: 5 of 46
- Biomaterials 39
- Oncology 47
- Molecular Biology 113
- Biochemistry 11
- Urology 6
Countries citing papers authored by K. Burk
This map shows the geographic impact of K. Burk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Burk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Burk more than expected).
Fields of papers citing papers by K. Burk
This network shows the impact of papers produced by K. Burk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Burk. The network helps show where K. Burk may publish in the future.
Co-authors
The 25 scholars most cited alongside K. Burk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2006 | 67 | |
| 2 | 1998 | 30 | |
| 3 | 1990 | 20 | |
| 4 | 1996 | 19 | |
| 5 | 1990 | 17 | |
| 6 | Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer. | 1989 | 9 |
| 7 | 2009 | 8 | |
| 8 | 1992 | 5 | |
| 9 | 1995 | 4 | |
| 10 | Weekly epirubicin in patients with hormone refractory prostatic cancer--a two-year follow-up. | 1989 | 3 |
| 11 | Weekly chemotherapeutic regimen in metastatic prostate cancer. | 1989 | 2 |
| 12 | 1994 | 2 | |
| 13 | 1989 | 2 | |
| 14 | Chemotherapy of hormone-resistant carcinoma of the prostate: 4-epi-rubicin weekly v.s. DMF monthly. | 1987 | 2 |
| 15 | 2006 | 1 | |
| 16 | 2006 | 1 | |
| 17 | 1995 | 1 | |
| 18 | 2024 | 1 | |
| 19 | Tur vs TUR plus adriamycin in patients with superficial bladder cancer--a five-year follow-up. | 1989 | 1 |
| 20 | 2009 | 0 |
About K. Burk
K. Burk is a scholar working on Oncology, Biophysics, Cardiology and Cardiovascular Medicine, Cancer Research and Pulmonary and Respiratory Medicine, having authored 21 papers that have together received 195 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (6 papers), Chemotherapy-induced cardiotoxicity and mitigation (4 papers), Bladder and Urothelial Cancer Treatments (4 papers), Electron Spin Resonance Studies (3 papers), Toxin Mechanisms and Immunotoxins (3 papers), Prostate Cancer Treatment and Research (2 papers), Ovarian cancer diagnosis and treatment (2 papers) and Cancer, Lipids, and Metabolism (2 papers). The work is most often cited by research in Biomaterials (39 citations), Oncology (47 citations), Molecular Biology (113 citations), Biochemistry (11 citations) and Urology (6 citations). K. Burk has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Klaus B. Mross, D. K. Hossfeld, Claus Bolling, Feliksas Jankevičius, Alvydas Česas, Axel-Rainer Hanauske, Marion Tina Weigel, Wolf‐Hartmut Meyer‐Moldenhauer, Ch. Manegold and Andreas Hüttmann. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, Investigational New Drugs, European Journal of Cancer, Journal of Emergency Medicine and European Journal of Clinical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.